Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Inspire Medical Systems Inc / Equity Bottom-Up

<ul><li>Inspire Medical Systems reported first quarter fiscal 2026 results characterized by modest revenue growth alongside ongoing challenges related to coding, reimbursement, and a government-mandated prior authorization program (WISeR).</li><li>Revenue increased 1.6% year-over-year to $204.6 million, driven primarily by increased market penetration, although this growth was partially offset by estimated adverse impacts totaling approximately $20 million in the quarter due to coding uncertainties and WISeR-related delays.</li><li>The company highlighted its efforts to manage these external headwinds through disciplined cost control, prioritizing revenue-generating activities, and investments aimed at long-term growth, including enhancements to patient care pathways, marketing, digital product experience, and research and development.</li></ul>

Inspire Medical Systems reported first quarter fiscal 2026 results characterized by modest revenue growth alongside ongoing challenges related to coding, reimbursement, and a government-mandated prior authorization program (WISeR).Revenue increased 1.6% year-over-year to $204.6 million, driven primarily by increased market penetration, although this growth was partially offset by estimated adverse impacts totaling approximately $20 million in the quarter due to coding uncertainties and WISeR-related delays.The company highlighted its efforts to manage these external headwinds through disciplined cost control, prioritizing revenue-generating activities, and investments aimed at long-term growth, including enhancements to patient care pathways, marketing, digital product experience, and research and development.

Inspire Medical Systems’ $150 Million Reimbursement Hit: Can Inspire V Still Deliver?